1. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.
- Author
-
Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, and Elahi D
- Subjects
- Aged, Blood Glucose metabolism, C-Peptide blood, Diabetes Mellitus, Type 2 metabolism, Drug Implants, Fasting, Fatty Acids, Nonesterified blood, Female, Glucagon adverse effects, Glucagon-Like Peptide 1, Glycated Hemoglobin metabolism, Humans, Injections, Subcutaneous, Insulin blood, Male, Peptide Fragments adverse effects, Protein Precursors adverse effects, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Glucagon administration & dosage, Peptide Fragments administration & dosage, Protein Precursors administration & dosage
- Abstract
Objective: Glucagon-like peptide 1 (GLP-1) is an insulinotropic gut hormone that, when given exogenously, may be a useful agent in the treatment of type 2 diabetes. We conducted a 3-month trial to determine the efficacy and safety of GLP-1 in elderly diabetic patients., Research Design and Methods: A total of 16 patients with type 2 diabetes who were being treated with oral hypoglycemic agents were enrolled. Eight patients (aged 75 +/- 2 years, BMI 27 +/- 1 kg/m(2)) remained on usual glucose-lowering therapy and eight patients (aged 73 +/- 1 years, BMI 27 +/- 1 kg/m(2)), after discontinuing hypoglycemic medications, received GLP-1 delivered by continuous subcutaneous infusion for 12 weeks. The maximum dose was 120 pmol x kg(-1). h(-1). Patients recorded their capillary blood glucose (CBG) levels (four times per day, 3 days per week) and whenever they perceived hypoglycemic symptoms. The primary end points were HbA(1c) and CBG determinations. Additionally, changes in beta-cell sensitivity to glucose, peripheral tissue sensitivity to insulin, and changes in plasma ghrelin levels were examined., Results: HbA(1c) levels (7.1%) and body weight were equally maintained in both groups. The usual treatment group had a total of 87 CBG measurements of
- Published
- 2003
- Full Text
- View/download PDF